×

Submissions for S2S 2019 are due November 2, 2018. Click HERE to submit a proposal.

ABOUT S2S

S2S is a forum for top scientists from around the world to present their ideas and interact with leading investors and executives in the Boston biotechnology hub.

Over 7 years, investigators from institutions including Brown, Carnegie Mellon, Columbia, Harvard, Johns Hopkins, MIT, Northwestern, NYU, Purdue, Scripps, UCLA, University of Iceland, University of Ottawa, University of Pennsylvania, University of Pittsburgh, Yale, and many more, have presented their startup ideas at S2S and its precursor, the University Research and Entrepreneurship Symposium (URES).

129

Projects Presented

40+

Universities Represented

13

Companies Started

150

Investors Attended in 2018

Who and What to Expect

Panels

Presentations

Networking Reception

S2S is an invitation-only symposium featuring the most innovative therapeutics startup ideas from the world’s top research institutions. Submissions from researchers are reviewed by a senior advisory group composed of experienced biotech investors. Selected presenters work 1-on-1 with advisory group mentors to further refine their concept and prepare a 15-minute presentation. 200+ attendees include entrepreneurs, biotech investors (Angels / VCs), pharma scouts, academic investigators, TTOs, etc.

WHEN AND WHERE

Tuesday, April 23, 2019

Full Day Event +
Evening Reception

Broad Institute
415 Main St., Cambridge

Process

1.
Proposal
Submissions Due

Nov 2

Academic researchers are invited to submit a one page overview of their therapeutic startup ideas.

2.
Semi-Finalists
Selected

Mid Nov

A subset of the researchers will be invited to submit a short slide deck.

3.
Finalists
Selected

Late Jan

Selected researchers will be invited to give a talk at the S2S Symposium.

4.
Mentorship
Program

Late Jan to April

Each presenter will work with matched advisors to refine their company strategy / final presentation.

5.
Science2Startup
Symposium

April 23rd

Full day event with presentations and panel discussions.

Advisors

And More...

Submissions

Successful S2S submissions are those that identify discoveries and technologies with the highest therapeutic potential and a tractable development path to clinical proof of concept. A one-page document outlining the topics listed below is required (click here for detailed guidelines). Additional supportive materials are also welcomed. Please only submit non-confidential materials.

Foundational scientific rationale and description of therapeutic approach

Differentiation over existing/competitive approaches with supporting data

Near-term research plan (next 12 months) and resources required

  • Accepted file types: pdf, xls, xlsx, doc, docx, ppt, pptx.
    File submissions should not exceed 30MB in aggregate.
    Accepted file types: pdf, xls, xlsx, doc, docx, ppt, pptx.
    Click the plus sign (+) to add additional files (max=5)
    *This field is required.
  • Accepted file types: pdf, xls, xlsx, doc, docx, ppt, pptx.
    File submissions should not exceed 30MB.
    Accepted file types: pdf, xls, xlsx, doc, docx, ppt, pptx.
    *This field is required.
  • Accepted file types: pdf, xls, xlsx, doc, docx, ppt, pptx.
    File submissions should not exceed 30MB.
    Accepted file types: pdf, xls, xlsx, doc, docx, ppt, pptx.
    *This field is required.
  • Accepted file types: pdf, xls, xlsx, doc, docx, ppt, pptx.
    File submissions should not exceed 30MB.
    Accepted file types: pdf, xls, xlsx, doc, docx, ppt, pptx.
    *This field is required.
  • Accepted file types: pdf, xls, xlsx, doc, docx, ppt, pptx.
    File submissions should not exceed 30MB.
    Accepted file types: pdf, xls, xlsx, doc, docx, ppt, pptx.
    *This field is required.
  • This field is for validation purposes and should be left unchanged.

Contact

To learn more about the event or to get involved, please email us at info@science2startup.com

Presented By

Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, we have been building breakthrough biotech startups since 1993. We work side by side with exceptional scientists and entrepreneurs to translate high impact science into medicines for patients. Our seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value.  For more information, please visit www.atlasventure.com.

F-Prime Capital is a global venture capital firm investing in life sciences, healthcare and technology. Since 1969, F-Prime has worked closely with entrepreneurs and academics to create innovative solutions to some of the world’s most significant challenges in healthcare and technology. For more information, please visit www.fprimecapital.com.

F-Prime Capital is a global venture capital firm investing in life sciences, healthcare and technology. Since 1969, F-Prime has worked closely with entrepreneurs and academics to create innovative solutions to some of the world’s most significant challenges in healthcare and technology. For more information, please visit www.fprimecapital.com.

Osage University Partners (OUP) is a venture capital fund that invests exclusively in startups that are commercializing university research. We firmly believe that universities provide an unparalleled innovation engine to launch disruptive startups. Hence, we have partnered with over 80 of the most entrepreneurial universities and research centers to invest in their startups and share part of our profits with those institutions to further promote the university entrepreneurial ecosystem. For more information, please visit osageuniversitypartners.com.

RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to provide seed funding to startups and to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with fewer capital concerns from inception through commercialization. For more information, please visit www.racap.com.

RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to provide seed funding to startups and to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with fewer capital concerns from inception through commercialization. For more information, please visit www.racap.com.

MassCONNECT is the exclusive mentorship partner of Science2Startup. MassBio’s MassCONNECT program is the only entrepreneur mentorship program in Massachusetts that dives deep into the life sciences. MassCONNECT matches entrepreneurs and founders with seasoned life sciences professionals to catalyze and commercialize innovation. Visit www.massbio.org/discover/massconnect to learn more.

Sponsors